SB-728-T
/ Sangamo Therap
- LARVOL DELTA
Home
Next
Prev
1 to 11
Of
11
Go to page
1
May 21, 2024
TRAILBLAZER: CCR5-modified CD4+ T Cells for HIV Infection
(clinicaltrials.gov)
- P1/2 | N=30 | Completed | Sponsor: University of Cincinnati | Active, not recruiting ➔ Completed
Trial completion • Human Immunodeficiency Virus • Infectious Disease • CD4
January 26, 2024
Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T
(clinicaltrials.gov)
- P=N/A | N=38 | Terminated | Sponsor: Sangamo Therapeutics | Trial completion date: Jun 2035 ➔ Jul 2023 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jun 2035 ➔ Jul 2023; There have been no significant safety issues in any subjects exposed between 7.5 and 13.5 years ago to either SB-728-T or SB-728mR-T, including no delayed adverse events related to the investigational product.
Trial completion date • Trial primary completion date • Trial termination • Human Immunodeficiency Virus • Infectious Disease
August 02, 2023
Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T
(clinicaltrials.gov)
- P=N/A | N=38 | Active, not recruiting | Sponsor: Sangamo Therapeutics | Enrolling by invitation ➔ Active, not recruiting | N=55 ➔ 38
Enrollment change • Enrollment closed • Human Immunodeficiency Virus • Infectious Disease • CD4
October 31, 2022
Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T
(clinicaltrials.gov)
- P=N/A | N=55 | Enrolling by invitation | Sponsor: Sangamo Therapeutics | Phase classification: P1 ➔ P=N/A | Trial completion date: Dec 2033 ➔ Jun 2035 | Trial primary completion date: Dec 2033 ➔ Jun 2035
Phase classification • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4
January 04, 2022
TRAILBLAZER: CCR5-modified CD4+ T Cells for HIV Infection
(clinicaltrials.gov)
- P1/2; N=30; Active, not recruiting; Sponsor: University of Cincinnati; Recruiting ➔ Active, not recruiting
Enrollment closed • Human Immunodeficiency Virus • Infectious Disease • CD4
March 01, 2021
Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T
(clinicaltrials.gov)
- P1; N=55; Enrolling by invitation; Sponsor: Sangamo Therapeutics; Trial completion date: Dec 2031 ➔ Dec 2033; Trial primary completion date: Dec 2031 ➔ Dec 2033
Clinical • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease
February 09, 2021
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
(clinicaltrials.gov)
- P1/2; N=8; Completed; Sponsor: Sangamo Therapeutics; N=12 ➔ 8
Clinical • Enrollment change • Human Immunodeficiency Virus • Immunology • Infectious Disease • CD4
December 17, 2019
Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T
(clinicaltrials.gov)
- P1; N=55; Enrolling by invitation; Sponsor: Sangamo Therapeutics
Clinical • New P1 trial
July 24, 2019
TRAILBLAZER: CCR5-modified CD4+ T Cells for HIV Infection
(clinicaltrials.gov)
- P1/2; N=30; Recruiting; Sponsor: Case Western Reserve University; Not yet recruiting ➔ Recruiting
Enrollment open
July 05, 2019
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
(clinicaltrials.gov)
- P1/2; N=12; Completed; Sponsor: Sangamo Therapeutics; Active, not recruiting ➔ Completed
Clinical • Trial completion
March 08, 2019
DELAYED VIRAL REBOUND DURING ATI AFTER INFUSION OF CCR5 ZFN-TREATED CD4 T CELLS
(CROI 2019)
- P1; "Introduction of CCR5 ZFNs via RNA transfection led to similar levels of disruption as Ad5/35 vectors. CTX led to an increase in engraftment and the administration of the product led to a modest, significant delay in viral rebound during the ATI and maintenance of low level viremia for up to 40 w in some, suggesting that a more efficient CCR5 modification could potentially benefit more individuals from this cure strategy."
1 to 11
Of
11
Go to page
1